MO D E L L O P E R I L C U R R I C U L U M V I T A E

Transcript

1 MO D E L L O P E R I L C U R R I C U L U M V I T A E INFORMAZIONI PERSONALI Cognome Nome GRIDELLI CESARE Data di nascita 24/03/1961 Qualifica DIRIGENTE MEDICO 2 LIVELLO Amministrazione A.O.R.N. SAN GIUSEPPE MOSCATI AVELLINO Incarico attuale DAL DICEMBRE 2001 DIRETTORE DI STRUTTURA COMPLESSA U.O. DI ONCOLOGIA MEDICA A.O.R.N. S.G. MOSCATI AVELLINO; DAL DICEMBRE 2003 DIRETTORE DEL DIPARTIMENTO DI ONCO- EMATOLOGIA, A.O.R.N. S.G. MOSCATI AVELLINO. Numero telefonico dell ufficio 0825/ OPPURE 0825/ Fax dell ufficio 0825/ istituzionale cegridelli@aosgmoscati.av.it TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE Titolo di studio LAUREA MEDICINA E CHIRURGIA Altri titoli di studio e professionali SPECIALIZZAZIONE IN: ONCOLOGIA MEDICA ; MEDICINA INTERNA Esperienze professionali (incarichi DICEMBRE 1993 ASSISTENTE, DIVISIONE DI ONCOLOGIA ricoperti) MEDICA B, ISTITUTO NAZIONALE TUMORI, NAPOLI; DICEMBRE 1995 DIRIGENTE I LIVELLO DIVISIONE DI ONCOLOGIA MEDICA B, ISTITUTO NAZIONALE TUMORI, NAPOLI; GENNAIO 2001 RESPONSABILE ( DIRIGENTE DI STRUTTURA SEMPLICE A CARATTERE DIPARTIMENTALE ) UNITA OPERATIVA DI CHEMIOTERAPIA AMBULATORIALE ISTITUTO NAZIONALE TUMORI, NAPOLI; DAL DICEMBRE 2001 DIRETTORE DI STRUTTURA COMPLESSA U.O. DI ONCOLOGIA MEDICA A.O.R.N. S.G. MOSCATI AVELLINO; DAL DICEMBRE 2003 DIRETTORE DEL DIPARTIMENTO DI ONCO- EMATOLOGIA, A.O.R.N. S.G. MOSCATI AVELLINO.

2 Capacità linguistiche Capacità nell uso delle tecnologie Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare) INGLESE PARLATO E SCRITTO ELEVATE Appartenenza a Società Associazione Italiana di Oncologia Medica Scientifiche: (A.I.O.M.) dal 1988 Membro del Consiglio Direttivo Nazionale dal 2006 al 2007 International Association for the Study of Lung Cancer (I.A.S.L.C.)

3 Oncology Expert Opinion on Pharmacotherapy Expert Review in Anticancer Therapy Tumori Expert Opinion in Biological Therapy Annals of Oncology Cancer Drugs Aging PharmacoEconomics Drug Safety The Oncologist Future Oncology Drugs of Today Anticancer Drugs Chest Cancer Therapy Respiration Clinical Lung Cancer Critical Review in Oncology/Hematology Expert Opinion on Emerging Drugs Drug Design, Development and Therapy Current Medical Literature- Lung Cancer Journal of Thoracic Oncology Journal of Postgraduate Medicine Cancer Chemotherapy and Pharmacology Cancer Treatment Reviews Therapeutics and Clinical Risk Management Journal of Medical Economics Journal of Gerontology:Medical Sciences Vascular Health and Risk Management Journal of the Pancreas Journal of Pathology British Journal of Cancer Journal of the National Cancer Institute Journal of Clinical Oncology Lancet Oncology Attività editoriale per riviste scientifiche: Corsi di management: Cancer Report dal 1993 al 2000 Cancer Edizione Italiana dal 1999 al 2002 Critical Reviews in Oncology/Hematology dal 2000 Cancer Aging dal 2003 The Oncologists dal 2003 (Section Editors Lung Cancer ) Supportive and Palliative Cancer Care dal 2004 Lancet Oncology dal 2006 Cancer dal 2006 Current Medical Literature- Lung Cancer dal 2007 Lung Cancer dal 2007 Therapeutic Advances in Medical Oncology dal 2008 Corso di management per medici dirigenti di II livello Ippocrate effettuato presso la Scuola di Direzione Aziendale dell Università Luigi Bocconi di Milano. Febbraio - Marzo - Aprile Autore di circa 600 pubblicazioni tra abstracts e lavori per estenso su riviste nazionali e internazionali (di cui circa 250 su riviste internazionali indexate). Il dottore Gridelli ha effettuato oltre 150 relazioni su invito e 60 moderazioni a convegni nazionali e oltre 60 relazioni su

4 invito e 20 moderazioni a convegni internazionali. Principali lavori pubblicati su riviste internazionali indexate: - C. Gridelli, F. Perrone, S. Palmeri et al.: "Mitomycin C plus vindesine plus etoposide (MEV) vs mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non small cell lung cancer: a phase III multicentre randomised trial." ANNALS OF ONCOLOGY, 7: , A. Gregor, A. Cull, R.J. Stephens, J.A. Kirkpatrik, J.R. Jarnold, D.J. Girling,... C. Gridelli (for Naples, Italy)...: Prophylactic cranial irradiation following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. EUROPEAN JOURNAL OF CANCER, 33: , C. Gridelli, F. Perrone, G.P. Ianniello et al: Carboplatin plus vinorelbine, a new well tolerated and active regimen for the treatment of extensive-stage small cell lung cancer: a phase II study. JOURNAL OF CLINICAL ONCOLOGY, 16: , C. Gridelli, F. Perrone, C. Gallo et al. on the behalf ELVIS group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall cell lung cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 91:66-72, JP van Meerbeeck, P Baas, C Debruyne, HJ Groen, C Manegold, A Ardizzoni, C. Gridelli, E van Marck, M Lentz, G Giaccone for the EORTC Lung Cancer Cooperative Group. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. CANCER, 85: , L Crinò, AM Mosconi, G Scagliotti, G Selvaggi, S Noviello, M Rinaldi, M Della Giulia, C Gridelli, A Rossi, C Calandri, F De Marinis, M Noseda, M Tonato. Gemcitabine as second line treatment for advanced non small cell lung cancer: a phase II trial. JOURNAL OF CLINICAL ONCOLOGY, 17: , L. Crinò, G.V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, M. Sari, S. Barni, A. Ravaioli, V. Adamo, L. Portalone, G. Cruciani, A. Masotti, G. Ferrara, F. Gozzelino, M. Tonato. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non small cell lung cancer: a randomized phase III study of the Italian Lung cancer Project. JOURNAL OF CLINICAL ONCOLOGY, 17: , The Italian Group for Antiemetic Research: Rolia F, Ballatori E, Ruggieri B, De Angelis V, Tonato M, Bosnjak S, Del Favero A,... Gridelli C. Dexamethasone alone or in combination with ondasetron for the prevention of delayed nausea and vomiting by chemotherapy. NEW ENGLAND JOURNAL OF MEDICINE, 342: , Gridelli C, Cortesi E, Roila F. Editorial Survival and quality of life: comparing end points in oncology. ANNALS OF ONCOLOGY, 12(SUPPL 3): S1, Perrone F, Gallo C, Gridelli C. Re: Cisplatin based therapy for elderly patients with advanced non small cell lung cancer: implication of Easter Cooperative Oncology Group 5592, a randomized trial. JOURNAL OF NATIONAL CANCER INSTITUTE, 94: 62-63, Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Gasparini G, Daletta D, Iaffaioli RV, Gebbia V. Chemotherapy for elderly patients with advanced non small cell lung cancer. The MILES (Multicenter Italian Lung cancer in the Elderly Study) phase 3 randomized trial.

5 JOURNAL OF NATIONAL CANCER INSTITUTE, 95:362-72, Gridelli C, Maione P, Airoma G, Rossi A. Selective cyclooxygenase-2 inhibitors and non small cell lung cancer CURRENT MEDICINAL CHEMISTRY, 9: , Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Barni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli Aa, Clerici M, Di Coistanzo F, Frontini L, Tonato M. Phase III randomized trial comparing three platinum doublets in advanced non small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 20: Gridelli C, Hainsworth J. Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC. LUNG CANCER 38(suppl 1):37-41, Gridelli C, Gallo C. Shepherd F, Illiano A, Piantedosi FV, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trial Group. JOURNAL OF CLINICAL ONCOLOGY, 21: , Gridelli C, Rossi A, Maione P. Treatment of non small cell lung cancer: state of the art and development of new biologic agents. ONCOGENE, 22: , Gridelli C, Maione P, Rossi A. Corticosteroids underemployement in delayed chemotherapy induced nausea and emesis with poor adherence to American Scociety of Clinical Oncology Guidelines: is this a reasonable clinical choice for the elderly?. JOURNAL OF CLINICAL ONCOLOGY, 21: , Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit patients affected by advanced in small cell lung cancer. BRITISH JOURNAL OF CANCER, 89: , Stahel R, Rossi A, Petruzelka L, Kosmidis P, de Braud F, Bernardo M, Souquet PJ, Soto Parra H and Gridelli C. Lessons from the Iressa expanded access programme: gefitinib in special non small cell lung cancer patient populations. BRITISH JOURNAL OF CANCER, 89(suppl2):19-23, Gridelli C, Ardizzoni A., Le Chavalier T., Manegold C., Perrone F, Thatcher N, van Zandwijk N, Di Maio M, Martelli O & De Marinis F. Treatment of advanced non small cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. ANNALS OF ONCOLOGY, 15: , Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F. Potential role of molecularly targeted therapy in the management of advanced non small cellllung carcinoma in the elderly. CANCER, 101: , Gridelli C, Manegold C, Mali P, Reck M, Portalone L, Castelnau O, Betticher D, Pless M, Pons JT, Aubert D, Burillon JP, Parlier Y, De Marinis F. Oral Vinorelbine given as monotherapy to advanced elderly patients: a multicenter phase II trial. EUROPEAN JOURNAL OF CANCER, 40: , Gridelli C, Gallo C, Di MaiooM, Barletta E, Illiano A, Maione P, Salvo S, Piantedosi FV, Palazzolo G, Caffo O, Cerebelli A, Falcone A, Mazzeo P, Brancaccio L, Captano MA, Iisa L, Barbera S, Perrone F. A randomised clinical trial of two docetaxel regimens in the second-line treatment of non small cell lung

6 cancer. The DISTAL 01 study. BRITISH JOURNAL OF CANCER, 91: , Perrone F, Di Maio M, Gallo C, Gridelli C. Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). JOURNAL OF CLINICAL ONCOLOGY, 22: , Gridelli C, Maione P, Rossi A, Di Maio M,and Perrone F. Chemotherapy of stage I to III Non-Small Cell Lung Cancer in the Elderly Patients. AMERICAN SOCIETY OF CLINICAL ONCOLOGY, EDUCATIONAL BOOK 41 ST ANNUAL MEETING MAY Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Pretis L, Di Maio M, Langer C. Treatment of advanced non small cell lung cancer in the elderly: results of an International Expert Panel. JOURNAL OF CLINICAL ONCOLOGY 23: , Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, cigolari S, Manzione L; Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F. Chemotherapy-induced neutropenia and treatment efficacy in advanced non small cell lung cancer: a pooled analysis of three randomised trias. LANCET ONCOLOGY, 6: , Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non small lung cancer: a review of the evidence. CHEST, 128:947-57, Maione P, Perrone F, Gallo C, Manzione L, Piantedosi FV, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C. Pretreatment qualità of life and functionallstatus assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study. JOURNAL OF CLINICAL ONCOLOGY, 23(28): Normanno N, DeLuca A, Macello MR, Gridelli C. Modulation of epidermal growth factor receptor positive circulating tumor cells by chemotherapy in non small cell lung cancer patients. JOURNAL OF CLINICAL ONCOLOGY, 23:7746-8, Maione P, Perrone F, Gallo C, Manzione L, Piantedosi FV, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Berretto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C. Pretreatment qualità of life and functional status assessment significantly predict survival of elderly patients with advanced non small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study. JOURNAL OF CLINICAL ONCOLOGY, 23: , Gridelli C, Rossi A, Maione P. New antiangiogenetic agents and non small cell lung cancer. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, Gridelli C. The use of biphosphonate in elderly cancer patients. THE ONCOLOGIST, 12:62-71, 2007.

7 - Gridelli C. Targeted therapies and non small cell lung cancer:new developments. CURRENT OPINION IN ONCOLOGY, 19:75-77, Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A. Sorafenib and sunitinib in the treatment of advanced non small cell lung cancer. ONCOLOGIST, 12: , Gridelli C. Does palliative chemotherapy beyond three courses benefit patients with non small cell lung cancer?. NATURE CLINICAL PRACTICE ONCOLOGY, 4: , Gridelli C, Aapro A, Barni S, Beretta GD, Colucci G, Daniele B, Del Mastro L, Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F. Role of colony stimulating factors (CSFs) in solid tumors: results of an experts panel. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 63:53-64, Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuttle W, Quoix E, Tsai CM, Gridelli C. Individual data meta-analysis of docetaxel administered once every 3 weeks compared to once every week second-line treatment of advanced non small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 25: , Gridelli C, Maione P, Rossi A. Single agent chemotherapy for the treatment of elderly patients with advanced non small cell lung cancer: what is the best drug?. JOURNAL OF CLINICAL ONCOLOGY, 25: , Gridelli C, Langer C, Maione P, Rossi A, Schild S. Lung cancer in the elderly. JOURNAL OF CLINICAL ONCOLOGY, 25: , Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carrozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Perrone F on thbehalf of the GECO Investigators. Factorial phase III randomised trial of rofecoxib and prolonged costant infusion of gemcitabine in advanced NSCLC: the GEmcitabine ad COxib in NSCLC (GECO) study.lancet ONCOLOGY, 8: , Gridelli C, Rossi A, Mongillo F, Bareschino M, Maione P, Ciardiello. A randomised phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non small cell lung cancer in elderly patients or patients with Performance Status of 2: treatment rationale and protocol dynamics. CLIN LUNG CANCER, 8: , Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non small cell lung cancer treatment: current status and future development. ONCOLOGIST, 12: , Gridelli C, Maione P, Iliano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati SF, Filipazzi V, Lo Russo V,Carozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small cell lung cancer: the MILES phase II study. JOURNAL OF CLINICAL ONCOLOGY, 10: , Gridelli C, Maione P, Rossi A, De Marinis F. The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments. ONCOLOGIST, 12: , 2007.

8 -Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, CrinòL, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scarrozzi M.Clinical significance and treatment of skin rash from erlotinib in non small cell lung cancer patients: results of an Experts Panel Meeting. CRITICAL REVIEW IN ONCOLOGY / HEMATOLOGY, 66: , Gridelli C, Rossi A, Morgillo F, Baraschino M, Maione P, Di Maio M, Ciardiello F. A randomised phase II study of pemetrexed or RAD001 as secondline treatment of advanced non small cell lung cancer in elderly patients: treatment rationale and protocol dynamics. CLIN LUNG CANCER, 8: , Gridelli C. Editorial. Treatment of advanced non small cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. JOURNAL OF CLINICAL ONCOLOGY, 26:13-16, Rossi A, Bria E, Gridelli C. Thalidomide in small cell lung cancer: is it a tombstone? JOURNAL OF CLINICAL ONCOLOGY, 26:160, Gridelli C. Targeted therapy developments in the treatment of non small cell lung cancer: a promising but long and winding road. CURRENT OPINION IN ONCOLOGY, 20: , Gridelli C, Maione P, Rossi A. The potential role of m-tor inhibitors in non small cell lung cancer. ONCOLOGIST, 13: , Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach J, Perrone F, Rosell R, Shepherd F, Thatcher N, Vansteenkiste J, De Pretis L, Di Maio M, De Marinis F. Second-line treatment of advanced non small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 3: , Rossi A, Torri W, Gridelli C. Paclitaxel plus bevacizumab for metastatic breast cancer. NEW ENGLAND JOURNAL OF MEDICINE, 358: , Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non small cell lung cancer. CRITICAL REVIEW IN ONCOLOGY HEMATOLOGY, 68:29-36, Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. An International, multicenter, randomized phase III study of first-line erlotinib followed by secondline cisplatin/gemcitabine versus first-line cisplatin-gemcitabine followed by second-line erlotinib in advanced non small cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. CLINICAL LUNG CANCER, 9: , Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Olivera AC, santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Gianniris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group.Gridelli C. Sorafenib in advanced hepatocellular carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 359: , Gridelli C. Editorial Histology-based treatment: a new era in the management of advanced non small cell lung cancer. CURRENT OPINION IN ONCOLOGY, 21:97-98,2009.

9 -Di Maio M, Chiodini P, Georgouilas V, Hatzidaki D. Wachter FM, Gebbia V, Smit EF, Morabito A, Gallo C; Perrone F, Gridelli C. Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, Gridelli C, Morabito A, Gebbia V,Mencoboni M, Carroozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. Catuximab and gemcitabine in elderly or adult patients with advanced non small cell lung cancer: the Cetuximab in advanced lung cancer (CALC-1E and CALC,PS2) randomized phase II trials. LUNG CANCER, Gridelli C, Maione P, Ferrara M, Rossi A. Cetuximab and other anti-epidrmal growth factors receptor monoclonal antibodies in the treatment of non small cell lung cancer. ONCOLOGIST, 14: , Gridelli C, Rossi A,Maione P, Rossi E, Castaldo V, Sacco PC, Colantuoni G. Vascular disrupting agents: a novel mechanism of action in the battle against non small cell lung cancer. ONCOLOGIST, 14: , Gridelli C, Maione P, Rossi A, Ferrara ML, Bareschino M, Schettino C, Sacco PC, Ciardiello F. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? ONCOLOGIST, 14: , , - -